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hypersensitivity syndromeFig. 1. Maculopapular rash on the back of the patient.Dear Editor,
Drug-induced hypersensitivity syndrome (DIHS) is a unique
adverse drug eruption, which causes reactivation of herpesviruses
such as human herpesvirus type-6 (HHV-6) during its clinical
course. DIHS has biphasic aspects of allergic reaction to drug and
of immune response to viral reactivation. Diagnostic criteria of
DIHS consists of 7 clinical features as previously described; macu-
lopapular rash, prolonged clinical symptoms, high fever, leukocyte
abnormalities, liver dysfunction, lymphadenopathy, HHV-6 reacti-
vation.1 However, it is not always easy to diagnose DIHS in an early
stage because its clinical features mimic macropapular rash-type
drug reaction or eruptions due to viral infection. It has recently
been reported that high serum level of thymus and activation-
regulated chemokine (TARC) is observed speciﬁcally in DIHS pa-
tients.2 We report a case of carbamazepine-induced DIHS, showing
extremely high serum level of TARC in an early stage, which helped
early diagnose of the disease.
An 86-year-old Japanese woman was referred to our hospital
because of widely spread erythema with itching. She had started
to take carbamazepine because of trigeminal neuralgia refractory
to non-steroidal anti-inﬂammatory drugs 1 month before she had
generalized rash. On admission, she had generalized rash with
facial edema (Fig. 1), pustules around her mouth, and a high fever
(over 38 C). Superﬁcial lymph nodes were not palpable. Her hepat-
ic failure was not remarkable, but renal failure was suggested (BUN
29.6 mg/dl, creatinine 1.29mg/dl). Eosinophil count was 3501/mm3
and CRPwas also high level (6.31mg/dl). We suspected DIHS in this
patient because of generalized rash developed after starting carba-
mazepine, high fever, and renal failure, but deﬁnite diagnosis of
DIHS was not made.
Her serum TARC level was extremely high (88,179 pg/ml), when
measured by utilizing HISCL® system (Sysmex, Hyogo, Japan) with
TARC Assay kit (Shionogi, Osaka, Japan). We considered that the
diagnosis was possibly DIHS and started prednisolone 30 mg/day
on day 2. From then, her temperature declined to the normal level,
and her rash and pustules were gradually disappeared. Since her
condition improved, prednisolone intake was gradually tapered.
After starting the prednisolone, her serum TARC level drastically
decreased as shown in Figure 2. Reactivation of HHV-6 was sus-
pected by increasing her serum HHV-6 IgG titers on day 25.Peer review under responsibility of Japanese Society of Allergology.
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mazepine was a culprit drug (stimulation index: 315%). We ﬁnally
gave a diagnosis of DIHS since this case had 6 out of 7 diagnostic
criteria of DIHS; maculopapular rash developing 1 month afterFig. 2. Serum TARC level of the patient.
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and liver abnormalities (ALT 316U/l on day 11), leukocytosis with
eosinophilia (WBC 13.1  109/l) and HHV-6 reactivation.
This case well supports the previous reports that serum TARC
level is extremely high at an active stage of DIHS in contrast to other
adverse drug reactions, such as StevenseJohnson syndrome.2,3
There are also some other skin diseases causing high serum level
of TARC, including atopic dermatitis, bullous pemphigoid, and
mycosis fungoides.4,5 However, their serum TARC level do not
exceed that of DIHS. In the present study we could not identify
the cells producing TARC, although its serum level was well corre-
lated with inﬂammatory condition of the patient. In the present
case, HISCL® systemwas utilized to measure the serum TARC level,
which enables us to show the result in a short time (17 min). This is
also helpful in comparison with a widely used TARC test, which
needs at least 2 or 3 days to ﬁgure out serum TARC level. In conclu-
sion, HISCL® system is very useful in diagnosing DIHS by rapid mea-
surement of serum TARC level in the patients with generalized
acute rash.
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